Antibody

AntibodystaleInstitut für Klinische Krebsfor…Phase 3

trastuzumab (Herceptin, FLOT + Herceptin/Pertuzumab)

Stomach Cancer; Gastroesophageal Junction Cancer · Stomach Cancer

#StomachCancer#Antibody#Phase3#항체#면역항체+3

AntibodystaleEli LillyPhase 3

FLOX (FLOX, 5-fluorouracil and folinic acid and oxaliplatin, FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 45.1%임상시험 1상태 ACTIVE

AntibodystaleThe Nordic Colorectal Cancer Bi…Phase 3

FLOX (FLOX, 5-fluorouracil/folinic acid/oxaliplatin, FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 45.1%임상시험 1상태 ACTIVE

AntibodystaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

AntibodystaleNanogen Pharmaceutical Biotechn…Phase 3

Faceptor (Faceptor)

Breast Cancer Metastatic; Breast Cancer Recurrent · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase3#항체#면역항체+3

AntibodystaleFudan UniversityPhase 2

Faminitib or bevacizumab (Faminitib or bevacizumab)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 3

Faricimab (Faricimab)

Age-Related Macular Degeneration; Diabetic Macular Edema · Non-Proliferative Diabetic Retinopathy

#Non-ProliferativeDiabeticRetinop#Antibody#Phase3#항체#면역항체+4

효능 ORR 16.9%임상시험 1상태 ACTIVE

AntibodystaleZarour, Hassane, MDPhase 2

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2

효능 ORR 1%임상시험 1상태 ACTIVE

AntibodystaleHI-Bio, A Biogen CompanyPhase 2

Felzartamab (Felzartamab)

Immunoglobulin A (IgA) Nephropathy · Immunoglobulin A (IgA) Nephropathy

#ImmunoglobulinAIgANephropathy#Antibody#Phase2#항체#면역항체+2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML